


#### Contents lists available at ScienceDirect

## **Tetrahedron**





Tetrahedron report number 845

## Recent advances in the synthesis of purine derivatives and their precursors

### Michel Legraverend

UMR176 CNRS, Institut Curie, Bât. 110 Centre Universitaire, 91405 Orsay, France

#### ARTICLE INFO

Article history: Received 19 May 2008 Available online 3 June 2008

Keywords: Purine libraries Purine chemistry ATP analogues Enzyme inhibitors Receptor antagonists

#### Contents

1.		luction	
2.	Funct	iionalisation at position 6	
	2.1.	Functionalisation of the purine ring from guanosine, via a 6-arylsulfonate intermediate	8586
	2.2.	Preparation of C-6-arylpurines	8587
	2.3.	Synthesis of 6-amidopurines	8587
	2.4.	Substitution reactions of 6-chloropurine and 2-amino-6-chloropurine with nucleophiles	8588
3.	Funct	tionalisation at position 9: preparation of 9-substituted purine derivatives	8589
	3.1.	Regioselective and stereoselective coupling of 6-(substituted-imidazol-1-yl)purines with 1-chloro-2'-deoxyribose	8589
	3.2.	Michael addition of adenine	8590
	3.3.	Arylation at N-9 of 7-deazapurines	8590
	3.4.	Arylation at N-9 of purines	8590
	3.5.	Mitsunobu alkylation at N-9 position with either primary or secondary alcohols	8591
	3.6.	Use of an aminoalkane and pyrimidine precursors	8591
4.	Functionalisation at N-1, N-3, N-7 and C-8		
	4.1.	Preparation of xanthine derivatives from 6-aminouracils (Traube synthesis)	8592
	4.2.	Synthesis of purines from an imidazole precursor	8592
	4.3.	Solid-phase synthesis of xanthine derivatives	
	4.4.	Synthesis of N-1,N-7-disubstituted purines from 6-chloropurine	8595
5.	Funct	tionalisation at position 2	
	5.1.	Pyrimidine precursors of 2,6,8,9-tetrasubstituted purines	8595
	5.2.	Synthesis of 2,6,8,9-tetrasubstituted purines	
	5.3.	Synthesis of 7-deazapurines (pyrrolo[2,3-d]pyrimidines) from pyrimidine precursors	8597
6.	Funct	tionalisation at position 8	
	6.1.	Synthesis of 8.9-disubstituted adenines	
	6.2.	Synthesis of 2.8.9-trisubstituted adenines	
		6.2.1. Synthesis of 2.8.9-trisubstituted adenine inhibitors of HSP90	
		6.2.2. 8-Aryl-9-methyladenine derivatives from a 4,6-dichloropyrimidine precursor	

Abbreviations: ATP, adenosine 5'-triphosphate; GTP, guanosine 5'-triphosphate; GDP, guanosine 5'-diphosphate; cGMP, cyclic adenosine 3',5'-monophosphate; cGMP, cyclic guanosine 3',5'-monophosphate; AcCoA, acetyl-coenzyme A; NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide adenine dinucleotide phosphate; FAD, flavin adenine dinucleotide; PAPS, 3'-phosphoadenosine 5'-phosphosulfate; SAM, 5'-S-adenosyl methionine.

E-mail address: michel.legraverend@curie.u-psud.fr

	6.3.	Synthesis of 6,7,8-trisubstituted purines	. 8599
	6.4.	Preparation of 6,8-disubstituted purine analogues: thiazolopyrimidines	8600
7.	Conclu	usions	8600
	Refere	ences and notes	8601
	Biogra	phical sketch	8603

#### 1. Introduction

The purine ring is the most ubiquitous nitrogen-containing heterocycle in nature, since, besides the numerous purine derivatives found in various marine organisms and plants, it is the core structure of adenine and guanine in nucleic acids (RNA and DNA). In addition, purines are involved in many metabolic processes as cofactors associated with a great number of enzymes and receptors, notably ATP, GTP, GDP, cAMP, cGMP, AcCoA, NAD, NADP, FAD, PAPS and SAM, 1,2 which play key roles at different phases of the cell cycle, in cell signalling and other fundamental biological processes.<sup>3</sup> It should be noted that all of these associated proteins contain a purine recognition pocket and, consequently, purine derivatives have long been developed to selectively inhibit or antagonise each of these enzymes and receptors. Indeed, a great variety of di-, tri- or tetrasubstituted purines described in the literature have been found to be potent inhibitors of chaperone HSP90, protein kinases (MAP, Src and Cdk), sulfotransferases, phosphodiesterases and microtubule assembly, inducers of interferon and dedifferentiation and antagonists of adenosine receptors and corticotropin-releasing hormone receptors.<sup>2</sup> This wide range of biological activities displayed by purines is conferred by a judicious choice of the nature of the substituents that can be combined on the N-1, C-2, N-3, C-6, N-7, C-8 and N-9 centres (Fig. 1).

$$\begin{array}{c|c}
1 & & & \\
2 & & & \\
N & & & \\
3 & & & \\
N & 9
\end{array}$$

Figure 1. Purine (imidazo[4,5-d]pyrimidine) ring.

With such an easy access to so much structural diversity, the purine core has become a privileged structure in medicinal chemistry, <sup>4</sup> and an important scaffold in the preparation of combinatorial libraries. In general, two strategies are applied for the preparation of purine libraries. In the first procedure, a preformed purine ring loaded with various reactive functionalities is directly modified, which allows good regiocontrol at C-2, C-6, C-8 and N-9. Alternatively, substituted pyrimidine or imidazole precursors are functionalised, generating the second heterocycle of the purine core in the process with better regiocontrol at N-1, N-3, N-7 and N-9.

Following a previous article, which highlights the interest in purines as inhibitors and modulators of key biological targets,<sup>2</sup> the goal of the present article is to review recent advances in the synthesis of purine derivatives, with particular emphasis on methods that can lead to purine libraries.

#### 2. Functionalisation at position 6

6-Aminopurines are traditionally obtained in four steps from a nucleoside precursor in a process, which requires protection of the sugar moiety followed by halide formation, often under harsh conditions. Interestingly, Wan and co-workers<sup>5</sup> have recently described the synthesis of several 6-aminopurine derivatives **2** in one step and high yield from unprotected inosine **1** (X=OH) (Scheme 1), by BOP-mediated amination.

Polycyclic aromatic hydrocarbons (PAH) are potent mutagens and carcinogens that are challenging synthetic targets. This method also allowed the synthesis of PAH derivative  $\bf 3$  from 2'-deoxyinosine  $\bf 1$  (X=H) as well as the rare DNA constituent  $\bf 4$  in almost quantitative yield.

Under these conditions, several 6-substituted purines **2a–h** (Table 1, entries 1–8) were prepared from unprotected inosine in high yield from various aryl- or benzylamines.

Using similar reaction conditions, the acetyl-protected inosine **5** led to the corresponding 6-substituted-9-(2,3,5-tri-O-acetyl- $\beta$ -D-ribofuranosyl)-purines **6a–g** (Scheme 2, Table 2, entries 1–7).

## 2.1. Functionalisation of the purine ring from guanosine, via a 6-arylsulfonate intermediate

The use of a 6-arylsulfonate for C–C bond formation with boronic acids at room temperature on the purine ring was reported for the first time in 2005. This palladium-catalysed cross-coupling reaction of nucleoside arylsulfonates and arylboronic acids required the use of a ligand and could be generalised to various boronic acids (Scheme 3).

The starting compound, 6-arylsulfonyl-3',5'-bis-O-(tert-butyl-dimethylsilyl)-2'-deoxyguanosine **7**, was synthesised from 2'-deoxyguanosine in high yield, in the presence of  $Et_3N$  and DMAP, with 2,4.6-trimethylphenylsulfonyl chloride.

Scheme 1.

### Download English Version:

# https://daneshyari.com/en/article/5227769

Download Persian Version:

https://daneshyari.com/article/5227769

**Daneshyari.com**